Vertex Pharmaceuticals Incorporated (VRTX) reported second-quarter 2024 adjusted loss per share of $12.83, which was wider than the Zacks Consensus Estimate of a loss of $11.50. In the year-ago quarter, Vertex recorded adjusted earnings of $3.89 per share. The significant loss in the quarter was due to costs related to the $4.9 billion acquisition of Alpine Immune Sciences, which was closed in May. The company reported total revenues of $2.65 billion, comprising cystic fibrosis (CF) product revenues. The fi ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) . Vertex currently has an average ...

Vertex Pharmaceuticals (VRTX) came out with a quarterly loss of $12.83 per share versus the Zacks Consensus Estimate of a loss of $11.50. This compares to earnings of $3.89 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.57%. A quarter ago, it was expected that this drugmaker would post earnings of $4.10 per share when it actually produced earnings of $4.76, delivering a surprise of 16.10%. Over the last four quarters, th ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $490.80, reflecting a +0.1% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily loss of 2.32%. Elsewhere, the Dow saw a downswing of 1.25%, while the tech-heavy Nasdaq depreciated by 3.64%. Coming into today, shares of the drugmaker had gained 3.48% in the past month. In that same time, the Medical sector gained 0.32%, while the S&P 500 gained 1.79%. The upcoming earnings release of Vertex ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned +3.5% over the past month versus the Zacks S&P 500 composite's +1.8% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has gained 3.9% over this period. Now the key question is: Where could the stock be headed in the near term? Earni ...

Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 1, 2024. The company is expected to report EPS of $4.14, up 6.43% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $2.64 billion, indicating a 6.01% increase compared to the same quarter of the previous year. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), po ...

- Three-year extension of collaboration to use genomics to accelerate drug discovery - - The range of therapeutic areas and genomic data insights will be expanded and the companies will also explore using genomic risk to better define patient subgroups - OXFORD, England, July 16, 2024 /PRNewswire/ -- Genomics plc (Genomics), a healthcare company transforming health through the power of genomics today announced a three-year extension of the company's collaboration with Vertex Pharmaceuticals Incorporated (Ve ...

Vertex Pharmaceuticals (VRTX) closed at $490.85 in the latest trading session, marking a +0.43% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.28%. Elsewhere, the Dow saw an upswing of 0.53%, while the tech-heavy Nasdaq appreciated by 0.4%. Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 1, 2024. The company is predicted to post an EPS o ...

So far this year, the stock has risen 16.5% against the industry's 4.6% decline. The stock has also outperformed the sector as well as the S&P 500. Estimates for Vertex's 2024 earnings have moved up from $16.88 to $17.06 over the past 60 days. New Products on the Way VRTX Stock Valuation Vertex is a great stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress. Consistently rising earnings estimates clearly highlight analysts' optimism about its abilit ...

Lilly is a good pick...but this one is better. Not exactly David vs. Goliath Sure, Vertex is much smaller than Lilly, with the latter's massive market cap at over $840 billion. But it's by no means small: Vertex's market cap tops $120 billion, making it one of the world's largest drugmakers. One nice plus for Vertex is that it enjoys a monopoly in treating the underlying cause of the rare genetic disease cystic fibrosis (CF). All four approved therapies that fit the bill are marketed by Vertex, including it ...